Gain expert insights on tardive dyskinesia. Activity topics range from screening and diagnosis to management in the face of psychiatric and other comorbidities.
In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia management from identification to follow-up, with a focus on VMAT2 inhibitors as a pharmacologic management strategy.
Listen to 2 thought leaders in the psychiatry field discuss the importance of screening for tardive dyskinesia in patients receiving antipsychotics, including clinical pearls for identification in various clinical settings.
A patient with tardive dyskinesia tells her story about the process of receiving an accurate diagnosis and how the disorder has affected her life.
Listen to Leslie, a patient with TD for the past 10 years, describe her experience with the disease from diagnosis to current impact on her daily life.
Tardive dyskinesia can be tricky to identify and manage. Here, Greg Mattingly, MD, describes the common mistakes he observes in TD care and how to avoid them in your clinical practice.
Listen to Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, discuss the utility of VMAT2 inhibitors for tardive dyskinesia. The experts also touch on off-label and emerging options for tardive dyskinesia, giving healthcare professionals a wealth of information on pharmacologic management.
Read this interactive case study by Sneha Mantri, MD, MS, demonstrating comprehensive and individualized care for a patient with bipolar disorder and recently developed tardive dyskinesia.
The risk of tardive dyskinesia has been a barrier to treating patients with antipsychotics. Now, however, there are treatment options available to treat tardive dyskinesia. Stephen R. Saklad, PharmD, BCPP, discusses the VMAT2 inhibitors and how they have revolutionized how we think about tardive dyskinesia.
Tardive dyskinesia exists in many patients—likely more than we are aware of. To connect these patients to treatment, we need to accurately identify the movement disorder. The Abnormal Involuntary Movement Scale is imperative to diagnosing and following patients with tardive dyskinesia in clinical practice.
The population of older patients with psychiatric conditions is increasing and, with it, the prevalence of tardive dyskinesia. Read on to gain a geropsychiatrist’s insights on preventing and managing TD in this vulnerable patient population.
Read this interactive case study by Jacob Ballon, MD, MPH, demonstrating the first steps of TD diagnosis and management in patients with primary mood disorders.
In this video roundtable activity, Christoph U. Correll, MD; Leslie Citrome, MD, MPH; and Amber Hoberg, PMHNP, discuss recently published articles of interest in tardive dyskinesia care.
Slides summarizing recent research in tardive dyskinesia.